U B M E D V I TA L L I N ES By Dirk Hoffman
CO-DEVELOPER OF MRNA VACCINES FOR COVID DELIVERS HARRINGTON LECTURE The scientist, who with a collaborator, invented and developed the messenger RNA (mRNA) technology that is the basis for PfizerBioNTech’s and Moderna’s COVID-19 vaccines, embodies the textbook definition of perseverance. Drew Weissman, MD, PhD, Roberts Family Professor in Vaccine Research at the Perelman School of Medicine at the University of Pennsylvania, spoke about his efforts to advance RNA technologies for use in vaccines on June 4 during Spring Clinical Day. The event brought to a close a yearlong celebration commemorating the 175th anniversary of the Jacobs School of Medicine and Biomedical Sciences.
Studies Begun in Obscurity Weissman was the keynote speaker for the Harrington Lecture and his talk, titled “Collaboration That Caught Fire: Decades of Research that Led to SARS-Cov-2 Vaccines,” detailed the arduous tasks he undertook in collaboration with Katalin Karikó, PhD, adjunct professor of neurosurgery at the University of Pennsylvania and a senior vice president at BioNTech. Weissman and Karikó have been studying RNA for use in vaccines for more than 15 years and have dreamed about the seemingly endless possibilities for treating diseases with custommade mRNA, but for many of the early years they did so in complete obscurity and without any funding. Weissman and Karikó are the recipients of the 2021 LaskerDeBakey Clinical Medical Research Award that often precedes a Nobel Prize; and the 2022 Breakthrough Prize in Life Sciences, the world’s largest science prize, among many other international awards. “The story of how Dr. Weissman and his collaborators maintained their focus and determination against formidable trials and tribulations is truly inspirational,” said Allison Brashear, MD, MBA, UB’s vice president for health sciences and dean of the Jacobs School of Medicine and Biomedical Sciences. Weissman and Karikó found a way to modify mRNA and later developed a delivery technique to package the mRNA in fat droplets called lipid nanoparticles (LNPs), Brashear noted as she introduced Weissman.
Curious and Creative Weissman said he was “highly honored” to be asked to deliver the Harrington Lecture and be a part of the school’s 175th anniversary celebration. “Medical schools are the foundation of basic science research in our country, so I am here to support all of basic science research,” he said.
2
2
BUFFALO PHARMACY MAGAZINE | 2022 FALL 2022 UB MEDICINE
Weissman said he is often asked what are the most important attributes of a researcher. “My response is always that there is not a particular personality. You do not have to be an introvert. You do not have to be a particular type of person to be a researcher,” he said. “But I do believe that you have to be curious and you have to be creative. And you need a level of intelligence to be able to take the creativity and develop new things and figure out how to turn those into true therapeutics.” Somewhat unexpectedly, Weissman also likened research to the arcade game of “whack-a-mole.” “You’re bright enough and you are creative. What happens then is new ideas keep popping into your mind,” he said. “And the question is, ‘what do you do with these new ideas? How do you decide which ideas are good and deserve to be followed up on?’ Science is a game of whack-a-mole. It’s finding the right project and hitting it.”
Collaboration and Perseverance Weissman went on to lay out the basic timeline on mRNA therapeutics. “I always laugh because when I talk to lay audiences, I always hear comments like, ‘Oh, I am afraid of this vaccine because it was invented in 10 months.’ And I have to say, ‘Well, that is not exactly true’—mRNA was discovered in 1961. The first time it was injected into an animal was 1990.” Weissman said what followed was a lot of collaborative research efforts, including those of his with Karikó, which he said started around 1998. “It wasn’t a simple step. It wasn’t somebody found RNA, they stuck it into an animal, made a vaccine and they were done,” he said. “It was hundreds and hundreds of people and thousands of experiments that people did together to develop mRNA therapeutics.” Weissman said he first started working with Karikó after they met at a copy machine. “Back in those days, the only way you could read a journal article was to photocopy the journal,” he said. “And we both read a lot and we both fought over the copy machine so we started talking.” He said they soon started collaborating on their research, but did not receive any grant funding until 2007— almost 10 years of work without any funding. “Katie and I would work side-by-side in the lab. We did not have any technicians or postdocs helping us do this,” Weissman said. “Katie would make the RNA and I would add it to cells or give it to mice. We would sit and discuss the results.” It was not until 2019 and 2020 that grants started to come a lot easier, he noted.
